Literature DB >> 10570196

Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus.

T Igarashi1, Y Endo, G Englund, R Sadjadpour, T Matano, C Buckler, A Buckler-White, R Plishka, T Theodore, R Shibata, M Martin.   

Abstract

Although simian/human immunodeficiency virus (SHIV) strain DH12 replicates to high titers and causes immunodeficiency in pig-tailed macaques, virus loads measured in SHIV(DH12)-infected rhesus monkeys are consistently 100-fold lower and none of 22 inoculated animals have developed disease. We previously reported that the administration of anti-human CD8 mAb to rhesus macaques at the time of primary SHIV(DH12) infection resulted in marked elevations of virus loads. One of the treated animals experienced rapid and profound depletions of circulating CD4(+) T lymphocytes. Although the CD4(+) T cell number partially recovered, this monkey subsequently suffered significant weight loss and was euthanized. A tissue culture virus stock derived from this animal, designated SHIV(DH12R), induced marked and rapid CD4(+) cell loss after i.v. inoculation of rhesus monkeys. Retrospective analyses of clinical specimens, collected during the emergence of SHIV(DH12R) indicated: (i) the input cloned SHIV remained the predominant virus during the first 5-7 months of infection; (ii) variants bearing only a few of the SHIV(DH12R) consensus changes first appeared 7 months after the administration of anti-CD8 mAb; (iii) high titers of neutralizing antibody directed against the input SHIV were detected by week 10 and persisted throughout the infection; and (iv) no neutralizing antibody against SHIV(DH12R) ever developed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570196      PMCID: PMC24188          DOI: 10.1073/pnas.96.24.14049

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro.

Authors:  Y J Zhang; T Dragic; Y Cao; L Kostrikis; D S Kwon; D R Littman; V N KewalRamani; J P Moore
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

2.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

3.  Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma.

Authors:  T Igarashi; C Brown; A Azadegan; N Haigwood; D Dimitrov; M A Martin; R Shibata
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

4.  Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

Authors:  R Shibata; T Igarashi; N Haigwood; A Buckler-White; R Ogert; W Ross; R Willey; M W Cho; M A Martin
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

5.  Simian-human immunodeficiency virus (SHIV) containing the nef/long terminal repeat region of the highly virulent SIVsmmPBj14 causes PBj-like activation of cultured resting peripheral blood mononuclear cells, but the chimera showed No increase in virulence.

Authors:  E B Stephens; S Mukherjee; Z Q Liu; D Sheffer; R Lamb-Wharton; K Leung; W Zhuge; S V Joag; Z Li; L Foresman; I Adany; O Narayan
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

7.  Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing.

Authors:  R Shibata; F Maldarelli; C Siemon; T Matano; M Parta; G Miller; T Fredrickson; M A Martin
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

8.  Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.

Authors:  M W Cho; M K Lee; M C Carney; J F Berson; R W Doms; M A Martin
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition.

Authors:  L M Rudensey; J T Kimata; E M Long; B Chackerian; J Overbaugh
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

10.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

Authors:  A K Pilgrim; G Pantaleo; O J Cohen; L M Fink; J Y Zhou; J T Zhou; D P Bolognesi; A S Fauci; D C Montefiori
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

View more
  45 in total

1.  Viral persistence in vivo through selection of neutralizing antibody-escape variants.

Authors:  A Ciurea; P Klenerman; L Hunziker; E Horvath; B M Senn; A F Ochsenbein; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.

Authors:  P S Silverstein; G A Mackay; S Mukherjee; Z Li; M Piatak; J D Lifson; O Narayan; A Kumar
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Biologic studies of chimeras of highly and moderately virulent molecular clones of simian immunodeficiency virus SIVsmPBj suggest a critical role for envelope in acute AIDS virus pathogenesis.

Authors:  M Haddrick; C R Brown; R Plishka; A Buckler-White; V M Hirsch; H Ginsberg
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.

Authors:  Rajeev Gautam; Yoshiaki Nishimura; Wendy R Lee; Olivia Donau; Alicia Buckler-White; Masashi Shingai; Reza Sadjadpour; Stephen D Schmidt; Celia C LaBranche; Brandon F Keele; David Montefiori; John R Mascola; Malcolm A Martin
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques.

Authors:  Tatsuhiko Igarashi; Ranjini Iyengar; Russel A Byrum; Alicia Buckler-White; Robin L Dewar; Charles E Buckler; H Clifford Lane; Kazuya Kamada; Akio Adachi; Malcolm A Martin
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

6.  Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration.

Authors:  Anil Kumar; Zhenqian Liu; Darlene Sheffer; Marilyn Smith; Dinesh K Singh; Shilpa Buch; Opendra Narayan
Journal:  Virology       Date:  2007-11-07       Impact factor: 3.616

7.  Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery.

Authors:  Keith Mansfield; Sabine M Lang; Marie-Claire Gauduin; Hannah B Sanford; Jeffrey D Lifson; R Paul Johnson; Ronald C Desrosiers
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

8.  Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes.

Authors:  Tatsuhiko Igarashi; Yasuyuki Endo; Yoshiaki Nishimura; Charles Buckler; Reza Sadjadpour; Olivia K Donau; Marie-Jeanne Dumaurier; Ronald J Plishka; Alicia Buckler-White; Malcolm A Martin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  Morphine and rapid disease progression in nonhuman primate model of AIDS: inverse correlation between disease progression and virus evolution.

Authors:  Vanessa Rivera-Amill; Peter S Silverstein; Richard J Noel; Santosh Kumar; Anil Kumar
Journal:  J Neuroimmune Pharmacol       Date:  2009-12-16       Impact factor: 4.147

10.  Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses.

Authors:  Yoshiaki Nishimura; Tatsuhiko Igarashi; Olivia K Donau; Alicia Buckler-White; Charles Buckler; Bernard A P Lafont; Robert M Goeken; Simoy Goldstein; Vanessa M Hirsch; Malcolm A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.